Format

Send to

Choose Destination
See comment in PubMed Commons below
J Hematol Oncol. 2012 Mar 18;5:10. doi: 10.1186/1756-8722-5-10.

Allogeneic hematopoietic stem cell transplantation in China: where we are and where to go.

Author information

1
Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11 Xizhimen South Street, Beijng 100044, China.

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and sometimes the only curative therapy for patients with certain hematological diseases. Allo-HSCT has been practiced in China for approximately 30 years, and great improvements have been made within the past decade, particularly in fields such as the haploidentical HSCT system, strategies to overcome relapse and GVHD, and modified HSCT for elderly patients. This review will describe the current situation and provide a prospective of these unique aspects of Allo-HSCT in China.

PMID:
22424172
PMCID:
PMC3353833
DOI:
10.1186/1756-8722-5-10
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center